The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs)
has the potential to provide an unlimited source of insulin-producing β cells for the treatment …

We detail a six-stage planar differentiation methodology for generating human pluripotent
stem cell–derived pancreatic β cells (SC-β cells) that secrete high amounts of insulin in …

An open-label, first-in-human phase 1/2 study is being conducted to evaluate the safety and
efficacy of pancreatic endoderm cells (PECs) implanted in non-immunoprotective …

These preliminary data from an ongoing first-in-human phase 1/2, open-label study provide
proof-of-concept that pluripotent stem cell-derived pancreatic endoderm cells (PEC-01) …

Type 1 diabetes is an autoimmune disorder in which the immune system attacks and
destroys insulin-producing islet cells of the pancreas. Although islet transplantation has …

Pancreatic islet transplantation has become an established approach to β-cell replacement
therapy for the treatment of insulin-deficient diabetes. Recent progress in techniques for islet …

Diabetes mellitus is a metabolic disorder that affects more than 460 million people
worldwide. Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells, whereas …

Transplantation of pancreatic progenitors or insulin-secreting cells derived from human
embryonic stem cells (hESCs) has been proposed as a therapy for diabetes. We describe a …

Transplantation of stem cell–derived β (SC-β) cells represents a promising therapy for type 1
diabetes (T1D). However, the delivery, maintenance, and retrieval of these cells remain a …

Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly
generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These …